New hope for tough prostate cancer: adding immunotherapy when standard drug fails
NCT ID NCT02312557
Summary
This study is testing if adding the immunotherapy drug pembrolizumab can help control advanced prostate cancer that has started growing again despite treatment with the standard drug enzalutamide. It involves about 58 men whose cancer has spread and is no longer responding to hormone-blocking therapy. The main goal is to see if the combination can reduce prostate-specific antigen (PSA) levels and slow the cancer's progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.